#retinitis_pigmentosa
LightNews LightNews
newsen.bsky.social
iRegene's NouvSight001 Receives Clinical Trial Clearance in the U.S. and China for Retinitis Pigmentosa#China#Chengdu#retinitis_pigmentosa#iRegene_Therapeutics#NouvSight001
iRegene's NouvSight001 Receives Clinical Trial Clearance in the U.S. and China for Retinitis Pigmentosa
iRegene Therapeutics advances its cell therapy NouvSight001, cleared for clinical trials in the U.S. and China, targeting retinitis pigmentosa.
third-news.com
September 29, 2026 at 5:47 AM
newsen.bsky.social
Projected Growth in Retinitis Pigmentosa Market from 2026 to 2036 Fueled by Advancements in Therapies#USA#Las_Vegas#gene_therapy#DelveInsight#retinitis_pigmentosa
Projected Growth in Retinitis Pigmentosa Market from 2026 to 2036 Fueled by Advancements in Therapies
The retinitis pigmentosa market is expected to see steady growth through 2036, driven by advances in gene therapies and increased awareness of retinal disorders.
third-news.com
September 29, 2026 at 2:36 PM
newsen.bsky.social
Nanoscope Therapeutics to Showcase Groundbreaking Data on Macular Degeneration and Retinitis Pigmentosa at Euretina Congress 2026#USA#Dallas#Nanoscope#retinitis_pigmentosa#MOGENRY
Nanoscope Therapeutics to Showcase Groundbreaking Data on Macular Degeneration and Retinitis Pigmentosa at Euretina Congress 2026
Nanoscope Therapeutics will present pivotal trial data on its optogenetic therapy at the Euretina Congress 2026, marking a milestone in vision restoration.
third-news.com
September 23, 2026 at 11:07 AM
newsen.bsky.social
Nanoscope Therapeutics Achieves Critical FDA Milestone for MOGENRY to Treat Severe Vision Loss#United_States#Dallas#Nanoscope#retinitis_pigmentosa#MOGENRY
Nanoscope Therapeutics Achieves Critical FDA Milestone for MOGENRY to Treat Severe Vision Loss
Nanoscope Therapeutics announces the FDA's acceptance of its Biologics License Application for MOGENRY, a gene therapy aimed at restoring vision for those suffering from severe retinitis pigmentosa.
third-news.com
September 9, 2026 at 11:16 AM
newsen.bsky.social
Nanoscope Therapeutics to Showcase Groundbreaking Analyses at 2026 Macula Society Annual Meeting#United_States#San_Diego#Nanoscope_Therapeutics#MCO-010#retinitis_pigmentosa
Nanoscope Therapeutics to Showcase Groundbreaking Analyses at 2026 Macula Society Annual Meeting
Nanoscope Therapeutics prepares to present post-hoc analyses at the Macula Society Annual Meeting, marking a significant milestone in retinal disease therapies.
third-news.com
February 24, 2026 at 12:22 PM
newsen.bsky.social
Nanoscope Therapeutics Unveils Promising Optogenetic Therapy Data at FLORetina-ICOOR 2025#United_States#Dallas#Nanoscope_Therapeutics#MCO-010#retinitis_pigmentosa
Nanoscope Therapeutics Unveils Promising Optogenetic Therapy Data at FLORetina-ICOOR 2025
Nanoscope Therapeutics presented groundbreaking results of its MCO-010 optogenetic therapy for retinal degeneration at the FLORetina-ICOOR 2025 Congress in Italy.
third-news.com
December 2, 2025 at 12:14 PM
newsen.bsky.social
Nanoscope Therapeutics Reveals Five-Year Safety Outcomes of MCO-010 Optogenetic Therapy for Retinitis Pigmentosa#USA#Dallas#Nanoscope_Therapeutics#MCO-010#retinitis_pigmentosa
Nanoscope Therapeutics Reveals Five-Year Safety Outcomes of MCO-010 Optogenetic Therapy for Retinitis Pigmentosa
Nanoscope Therapeutics announces promising long-term safety results from its MCO-010 therapy study for retinitis pigmentosa, highlighting positive outcomes.
third-news.com
November 4, 2025 at 12:11 PM
newsen.bsky.social
Nanoscope Therapeutics Celebrates Groundbreaking Results in Retinitis Pigmentosa Treatment with MCO-010#USA#Dallas#Nanoscope_Therapeutics#MCO-010#retinitis_pigmentosa
Nanoscope Therapeutics Celebrates Groundbreaking Results in Retinitis Pigmentosa Treatment with MCO-010
Nanoscope Therapeutics reveals promising three-year results for MCO-010, a potential breakthrough therapy for retinitis pigmentosa with significant vision restoration.
third-news.com
October 22, 2025 at 11:25 AM
newsen.bsky.social
Nanoscope Unveils Pioneering 3-Year REMAIN Trial Results for Vision Restoration#USA#Dallas#Nanoscope#MCO-010#retinitis_pigmentosa
Nanoscope Unveils Pioneering 3-Year REMAIN Trial Results for Vision Restoration
Nanoscope Therapeutics reveals significant data from their REMAIN trial for retinitis pigmentosa, highlighting advancements in vision restoration therapies.
third-news.com
August 26, 2025 at 11:18 AM
newsen.bsky.social
Nanoscope Therapeutics to Present Groundbreaking Data at the 2025 ASRS Annual Meeting#USA#Long_Beach#Nanoscope_Therapeutics#MCO-010#retinitis_pigmentosa
Nanoscope Therapeutics to Present Groundbreaking Data at the 2025 ASRS Annual Meeting
Nanoscope Therapeutics will showcase crucial data on its MCO-010 therapy for Retinitis Pigmentosa at the 2025 ASRS Annual Meeting, highlighting significant efficacy and safety.
third-news.com
July 28, 2025 at 12:13 PM
newsen.bsky.social
Nanoscope Therapeutics Takes Major Step for Gene-Agnostic Therapy in Retinitis Pigmentosa#United_States#Dallas#Nanoscope_Therapeutics#MCO-010#retinitis_pigmentosa
Nanoscope Therapeutics Takes Major Step for Gene-Agnostic Therapy in Retinitis Pigmentosa
Nanoscope Therapeutics has initiated a rolling submission for FDA approval of MCO-010, the first gene-agnostic therapy aimed at treating retinitis pigmentosa.
third-news.com
July 14, 2025 at 11:07 AM
newsen.bsky.social
Skyline Therapeutics Unveils Innovative Gene Therapy for Vision Loss at ASGCT 2025#None#New_Orleans#retinitis_pigmentosa#Skyline_Therapeutics#SKG1108
Skyline Therapeutics Unveils Innovative Gene Therapy for Vision Loss at ASGCT 2025
Skyline Therapeutics showcases their groundbreaking gene therapy, SKG1108, aimed at restoring vision in Retinitis Pigmentosa patients. Join the advancements.
third-news.com
May 10, 2025 at 4:12 PM
newsen.bsky.social
LUXTURNA's Dominance in Retinal Gene Therapy: Market Trends and Insights#United_States#Las_Vegas#gene_therapy#retinitis_pigmentosa#LUXTURNA
LUXTURNA's Dominance in Retinal Gene Therapy: Market Trends and Insights
LUXTURNA is making significant strides in the retinal gene therapy market, addressing the urgent need for effective treatments in genetic conditions.
third-news.com
March 26, 2025 at 9:42 PM
newsen.bsky.social
Nanoscope Breaks New Ground in Restoring Vision for Retinitis Pigmentosa Patients#USA#Dallas#Vision_Restoration#Nanoscope#retinitis_pigmentosa
Nanoscope Breaks New Ground in Restoring Vision for Retinitis Pigmentosa Patients
Nanoscope Therapeutics reveals groundbreaking findings on restoring vision in retinitis pigmentosa patients via innovative synthetic opsin therapy.
third-news.com
March 24, 2025 at 8:47 PM
newsen.bsky.social
First Patient Receives RV-001 in Pioneering Gene Therapy Trial for Retinitis Pigmentosa#Japan#Tokyo#Restore_Vision#RV-001#retinitis_pigmentosa
First Patient Receives RV-001 in Pioneering Gene Therapy Trial for Retinitis Pigmentosa
Restore Vision has successfully dosed the first patient in a groundbreaking Phase I/II trial of RV-001, addressing vision loss in retinitis pigmentosa.
third-news.com
February 13, 2025 at 7:06 AM